Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 36 of 228 for:    yeast

Effect of Oral Probiotic Yeast on the Composition of the Vaginal Microbiota in Healthy Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03574844
Recruitment Status : Completed
First Posted : July 2, 2018
Last Update Posted : May 21, 2019
Sponsor:
Collaborator:
Biofortis Mérieux Nutriscience
Information provided by (Responsible Party):
Lesaffre International

Brief Summary:
This study is designed to evaluate the impact of oral consumption of the probiotic yeast CNCM I-3856 on healthy vaginal microbiota

Condition or disease Intervention/treatment Phase
Vaginal Health Dietary Supplement: Saccharomyces cerevisiae, dose 500 Dietary Supplement: Saccharomyces cerevisiae, dose 1000 Dietary Supplement: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, double-blind, placebo-controlled, 3 parallel-arms, pilot clinical study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomized, Double-blind, Placebo-controlled Clinical Study Evaluating the Effect of Oral Probiotic Yeast on the Composition of the Vaginal Microbiota in Healthy Women
Actual Study Start Date : March 1, 2018
Actual Primary Completion Date : January 15, 2019
Actual Study Completion Date : February 15, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Saccharomyces cerevisiae, dose 500
Saccharomyces cerevisiae CNCM I-3856, 500 mg per day (2 capsules), for 4 weeks
Dietary Supplement: Saccharomyces cerevisiae, dose 500
Experimental arm

Experimental: Saccharomyces cerevisiae, dose 1000
Saccharomyces cerevisiae CNCM I-3856, 1 g per day (2 capsules), for 4 weeks
Dietary Supplement: Saccharomyces cerevisiae, dose 1000
Experimental arm

Placebo Comparator: Placebo
Maize starch and magnesium stearate, 1 g per day (2 capsules), for 4 weeks
Dietary Supplement: Placebo
Placebo comparator arm




Primary Outcome Measures :
  1. S cerevisiae transfer from the gut to the vagina [ Time Frame: Day 28 ]
    Proportion of subjects presenting the yeast strain S cerevisiae CNCM I-3856 (presence) in their vaginal microbiota after a 4-week daily supplementation


Secondary Outcome Measures :
  1. S cerevisiae transfer from the gut to the vagina [ Time Frame: Day 7, Day 14, Day 21, Day 42 ]
    Proportion of subjects presenting the yeast strain S cerevisiae CNCM I-3856 (presence) in their vaginal microbiota after 1, 2 or 3-week daily supplementation and after a 2-week observation period without supplementation

  2. Quantification of S cerevisiae in the vagina [ Time Frame: Day 7, Day 14, Day 21, Day 28, Day 42 ]
    Value at Day 7, 14, 21, 28, 42 and change Day 42 - Day 28 of S cerevisiae CNCM I-3856 (CFU/ sample) in the vaginal microbiota

  3. Impact on 4 predominant Lactobacilli species [ Time Frame: Day 7, Day 14, Day 21, Day 28, Day 42 ]
    Changes of 4 dominant Lactobacilli species (number of copies per sample) by comparison of the 3 groups at each time change

  4. Association between intestinal and vaginal microbiota for the presence of S cerevisiae CNCM I-3856 [ Time Frame: Day 7, Day 14, Day 21, Day 28, Day 42 ]
    Evaluation of the presence of S cerevisiae CNCM I-3856 in the vaginal microbiota considering its presence in the intestinal microbiota in each active group.

  5. Correlation between the quantity of S cerevisiae CNCM I-3856 (CFU/sample) in the intestinal microbiota and vaginal microbiota [ Time Frame: Day 7, Day 14, Day 21, Day 28, Day 42 ]
    Correlation between the quantity of S cerevisiae CNCM I-3856 (CFU/sample) in the intestinal microbiota and vaginal microbiota in each active group.

  6. Presence of Candida albicans in the vaginal microbiota [ Time Frame: Day 7, Day 14, Day 21, Day 28, Day 42 ]
    In each group, at each time point according to Day 0 and at Day 42 according to Day 28

  7. Evolution of the presence of Candida albicans in the vaginal microbiota [ Time Frame: Day 7, Day 14, Day 21, Day 28, Day 42 ]
    Changes of Candida albicans (CFU/samples) in the vaginal microbiota



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Caucasian or Asian women,
  • With regular menstrual cycles, assessed as 28 days ± 3 days,
  • With a normal vaginal flora : Nugent score ≤ 3,
  • With the same efficient contraception method since at least 3 months before the start of the study, and accepting to maintain this program over the study. Authorized contraception methods: hormonal contraception (pill, patch, implant and intrauterine device), tubal ligation, ESSURE system and copper intrauterine device (without hormone),
  • Agreeing to keep unchanged her intimate hygiene rules during the all duration of the study (same stable intimate hygiene habits since at least 3 months before the start of the study),
  • Good general and mental health compatible with the study participation and allowing to be followed in ambulatory way according to the investigator opinion: no clinically significant and relevant abnormalities of medical history or physical examination;
  • Having stable life habits since at least 3 months and accepting to maintain them stable during the study (dietary habits, tobacco and alcohol consumptions, physical activity and sexual activity),
  • Tobacco consumption ≤ 10 cigarettes per day,
  • Able and willing to participate to the study by complying with the protocol procedures (especially concerning study product consumption and biological samples collections), as evidenced by her dated and signed informed consent form,
  • Affiliated with a social security scheme,
  • Agreeing to be registered on the national file of volunteers participating in biomedical research.

Exclusion Criteria:

  • Having hypersensitivity history to one of the ingredients of the study products,
  • Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other uncontrolled metabolic disorder,
  • Suffering from a severe chronic disease (e.g. cancer, renal failure, hepatic or biliary disorders ongoing, chronic inflammatory digestive disease, arthritis, chronic respiratory trouble, chronic gastro-intestinal disorder, cardiac disease, immunodeficiency…) or diseases found to be inconsistent with the conduct of the study by the investigator (controlled arterial hypertension accepted),
  • Suffering from Sexually Transmitted Infection (STI) or Disease (STD) such as HIV (Human Immunodeficiency Virus), B and C hepatitis, HPV (Human PapillomaVirus), Chlamydia infection, syphilis, gonorrhea, genital herpes, etc,
  • Currently suffering or having suffer from bacterial, fungal, parasitic or viral infection of the uro-gynecological sphere (vaginitis, cystitis, cervix infection…), treated or not, in the 6 months previous to the study start,
  • Having medical history or current pathology which could affect the study results or expose the subject to an additional risk according to the investigator,
  • Currently pregnant, or lactating, intending to be pregnant within 2 months ahead or pregnancy and/or breastfeeding finished since less than 3 months,
  • Ongoing symptoms of vaginal and/or urinary infection (belong to symptoms questionnaire) at the moment of the V0 and V1 visits,
  • Recent history of radiotherapy (less than 6 months),
  • Menopausal or pre-menopausal,
  • With menstruation which usually lasts more than 7 days,
  • Under chronic treatment with corticosteroids and/or immune modulator (immunostimulant, immunosuppressant…) or last intake within 3 months before the start of the study,
  • Currently under medication or dietary supplement, oral or local, which could affect study parameters: antibiotic, antifungal, probiotic, prebiotic, symbiotic, phytoestrogens, etc, or stopped within a too short time window before study start (less than 4 weeks) ,

    .- Having a lifestyle deemed incompatible with the study according to the investigator (specific diet (vegetarian, vegan, hypocolaric…), alcohol consumption > 2 glasses / day, physical activity > 10 hours / week…),

  • With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,
  • Planning to travel for a long time during the study duration or not able to be contacted for emergency reason during the study available,
  • Presenting a psychological or linguistic incapacity to understand and sign the informed consent,
  • Participating in another clinical trial or in exclusion period from a previous clinical trial,
  • Having received, during the last 12 months, countervailing indemnities for clinical trial higher or equal to 4500 Euros,
  • Under legal protection (guardianship, wardship) or deprived from her rights following judicial or administrative decision.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03574844


Locations
Layout table for location information
France
Biofortis Mérieux Nutriscience
Saint-Herblain, France, 44800
Sponsors and Collaborators
Lesaffre International
Biofortis Mérieux Nutriscience

Layout table for additonal information
Responsible Party: Lesaffre International
ClinicalTrials.gov Identifier: NCT03574844     History of Changes
Other Study ID Numbers: 2017-A02709-44
First Posted: July 2, 2018    Key Record Dates
Last Update Posted: May 21, 2019
Last Verified: June 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No